Literature DB >> 1453606

Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy.

M H Lafage1, C Combe, A Fournier, M Aparicio.   

Abstract

The effects of a very low-protein diet (VLPD) supplemented with amino acids and ketoanalogues (KA) and with 1 g of calcium carbonate and 1000 IU of vitamin D2, were studied in 17 patients with advanced renal failure (GFR < or = 20 ml/min) over a period of one year. The protein intake was 0.3 g protein/kg body wt/day. Daily phosphorus and calcium intake were respectively 1,500 mg and 300 mg. Sequential bone densitometry was performed and bone histomorphometry after double tetracycline labeling was evaluated, before and after one year of diet. Calcium and phosphate metabolism parameters were monitored every two months. In spite of a significant decrease of GFR, phosphorus, parathyroid hormone (1-84) and osteocalcin plasma levels decreased significantly, while low plasma bicarbonate normalized, and calcitriol and calcium levels remained respectively low and normal. Before the diet, histological study disclosed four cases of mixed osteopathy: osteomalacia associated with osteitis fibrosa (OM/OF), nine pure osteitis fibrosa (OF) and four with normal bone remodeling (NB). After one year of diet, the OM component of OM/OF disappeared, as evidenced by a normalization of the mineral apposition rate and osteoid thickness. In the patients presenting pure OF, a significant decrease in osteoblastic and osteoclastic surfaces, in the number of osteoclasts, and in the bone formation rate (BFR) were found. Vertebral mineral density measured by quantitative computerized tomodensitometry did not change significantly. In conclusion, this study not only confirms the beneficial effects of VLPD + KA + calcium on uremic hyperparathyroid bone disease in advanced renal failure assessed using static bone histomorphometry, but also shows a correction of histodynamic bone parameters.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1453606     DOI: 10.1038/ki.1992.407

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

1.  Effect of alfacalcidol on renal bone disease in mild to moderate renal failure. Questions remain over alfacalcidol's efficacy in preventing secondary hyperparathyroidism.

Authors:  A Fournier; N E Esper; P Moriniere; R Oprisiu; A Marie
Journal:  BMJ       Date:  1995-07-08

2.  Parathyroid hormone gene expression in hypophosphatemic rats.

Authors:  R Kilav; J Silver; T Naveh-Many
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

3.  Loss via peritoneal fluid as a factor for low 25(OH)D3 level in peritoneal dialysis patients.

Authors:  Garip Sahin; Ismail Kirli; Basar Sirmagul; Ertugrul Colak; Ahmet Ugur Yalcin
Journal:  Int Urol Nephrol       Date:  2009-04-29       Impact factor: 2.370

4.  Vitamin D insufficiency and hyperparathyroidism in children with chronic kidney disease.

Authors:  Shina Menon; Rudolph P Valentini; Guillermo Hidalgo; Lena Peschansky; Tej K Mattoo
Journal:  Pediatr Nephrol       Date:  2008-06-25       Impact factor: 3.714

Review 5.  Calcium, phosphate, vitamin D, and the parathyroid.

Authors:  K H Marks; R Kilav; T Naveh-Many; J Silver
Journal:  Pediatr Nephrol       Date:  1996-06       Impact factor: 3.714

6.  Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D.

Authors:  T Naveh-Many; R Rahamimov; N Livni; J Silver
Journal:  J Clin Invest       Date:  1995-10       Impact factor: 14.808

Review 7.  Recent Advances in the Role of Diet in Bone and Mineral Disorders in Chronic Kidney Disease.

Authors:  Orlando M Gutiérrez
Journal:  Curr Osteoporos Rep       Date:  2021-11-03       Impact factor: 5.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.